Regular screening for prostate cancer could cut the number of deaths from the disease by one fifth, despite doubts about the diagnostic test used, a major study has found.
Over a period of nine years, screening reduced the number of men dying from prostate cancer by 15%, increasing to 22% after 11 years, according to data from the European Randomised study of Screening for Prostate Cancer (ERSPC).
Some 162,000 men aged 50 to 74 from eight European countries - Belgium, Finland, France, Italy, the Netherlands, Spain, Sweden and Switzerland - took part in the research.
The diagnostic test is controversial because it measures blood levels of the biomarker prostate specific antigen (PSA), which is so unreliable.
Higher than normal PSA has been found in healthy men and visa versa in patients who already have prostate cancer.
More top news
Team Sky's Chris Froome is set to win the 2016 Tour de France with an overall lead of four minutes 11 seconds after stage 20 to Morzine
The attempted kidnap of an RAF serviceman took place near RAF Marham, in Norfolk, on Wednesday.
Footballer Marc Crosas faces an investigation after pictures emerged of him appearing to have speared an endangered baby shark